唐氏综合征(DS)是一种染色体异常,其特征是21号染色体。DS患者的眼科表现患病率很高。
回顾科学证据并评估DS儿童人群中眼科表现的患病率。
电子数据库,包括MEDLINE,科克伦图书馆,EMBASE,ScienceDirect,和LILACS。
包括已发表的观察性研究以及现有的原始数据。如果研究设计是回顾,则文章被排除在外,给编辑的信,病例报告,案例系列,或系统评价,以及受试者是否有继发于其他疾病的眼科表现。
患有DS和眼科评估的儿科和青少年人群。
在Excel中设计了一个数据收集表单。五名审稿人提取了每项研究的设计和结果的相关细节。通过应用JoannaBriggs研究所对患病率和发病率进行系统评价的工具来评估研究质量。我们计算了眼科表现的加权患病率,只考虑报告每种表现形式测量的研究。
22篇文章(来自15个国家,1994-2020年期间发表的)被纳入本系统综述。在85%的DS儿童和青少年人群中观察到眼部表现。最常见的是倾斜裂缝,斜裂缝,震中,和眼睑。
患有DS的儿童和青少年人群的眼部表现多种多样,有些会不可逆转地影响视觉发育。应从出生后的头几个月开始对患有DS的儿科人群进行筛查,并每年继续进行。
PROSPEROCRD42019127717。
Down syndrome (DS) is a chromosomal anomaly that is characterized by an extra chromosome 21. Ophthalmological manifestations have a high prevalence in patients with DS.
To review the scientific evidence and estimate the prevalence of ophthalmological manifestations in the pediatric population with DS.
Electronic databases including MEDLINE, Cochrane Library, EMBASE, ScienceDirect, and LILACS.
Published observational studies with available and original data were included. Articles were excluded if the study design was a review, letter to the editor, case report, case series, or systematic review and if the subjects had ophthalmological manifestations secondary to other conditions.
Pediatric and adolescent population with DS and with ophthalmological evaluation.
A data collection form was designed in Excel. Five reviewers extracted relevant details about the design and results of each study. The quality of the studies was assessed by applying the tools for systematic reviews of prevalence and incidence from the Joanna Briggs Institute. We calculated the weighted prevalence of ophthalmological manifestations, considering only the studies reporting the measurement of each manifestation.
Twenty-two articles (from 15 countries, published during 1994-2020) were included in the present systematic review. Ocular manifestations were observed in 85% of the studied pediatric and adolescent populations with DS. The most frequent ones were slanting fissures, oblique fissures, epicanthus, and epiblepharon.
The ocular manifestations in the pediatric and adolescent populations with DS are varied, and some can irreversibly affect visual development. Screening of the pediatric population with DS should be conducted from the first months of age and continued annually.
PROSPERO CRD42019127717.